INCRELEX (mecasermin) - Important Safety Information from Ipsen Pharmaceuticals Ltd as approved by the HPRA

Notice type: 3rd Party Publications

Date: 12/12/2019

 

Problem Or Issue:

Important Safety Informatio from Ipsen Pharmaceuticals  Ltd on risk of benign and malignant neoplasia of INCRELEX 10mg/ml Solution for Injection (mecasermin)


Important Safety Information - INCRELEX (mecasermin)





« Back